UnknownNot Applicable

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

Italy104 participantsStarted 2014-12-15

Plain-language summary

Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ability to understand and the willingness to sign a written informed consent document
✓. Male aged \>18 years with metastatic castration-resistant disease with documented clinical (imaging) and/or biochemical progression (PSA increasing values) during or after a previous docetaxel-based chemotherapy
✓. Patients must have metastatic and/or inoperable disease
✓. Patients must have received prior therapy docetaxel based and must be candidate to cabazitaxel
✓. Life expectancy of greater than 3 months
✓. Eastern Cooperative Oncology Group (ECOG) performance status \<2

Exclusion criteria

✕. Participants who are unable to provide informed consent
✕. Participation in another clinical trial

What they're measuring

Progression free survival (PFS)

Timeframe: 36 months

Trial details

NCT IDNCT03381326

SponsorIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-10

View on ClinicalTrials.gov More Prostate Cancer trials